-+ 0.00%
-+ 0.00%
-+ 0.00%

Zymeworks To Announce Presentations Highlighting Breadth Of Oncology Portfolio At ASCO And ESMO Conferences

Benzinga·05/22/2025 21:22:07
Listen to the news
  • Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodies
  • Long-term outcomes and survival data for Ziihera® (zanidatamab-hrii), which was developed using Azymetric™, to be presented at ASCO and highlight its potential to transform the treatment landscape for first-line HER2-positive gastroesophageal cancer
  • ZW171 Trial-in-Progress (TiP) poster at ASCO, ZW191 TiP poster at ESMO Gynaecological Cancers Congress; trial enrollment remains on track

VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced multiple presentations related to its oncology programs at upcoming medical conferences, including the American Society of Clinical Oncology (ASCO) Annual Meeting, and the European Society of Medical Oncology (ESMO) Gynaecological Cancers Congress.